Sarah Foster Adams

Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0

Jamie L. Lesnock, Sarah Temin, Sara Bouberhan, Sarah Foster Adams et autres

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. PURPOSE To provide guidance regarding the systemic treatment of patients with high-grade serous and/or endometrioid epithelial ovarian, …

us, cr, jp (code pays fourni par la source)

Rethinking ovarian cancer III: the past decade and future directions

Frances R. Balkwill, Céline M. Laumont, Nikki L. Burdett, Olivia Le Saux et autres

gb, ca, au, fr, us, fi, ch (code pays fourni par la source)

875 PARP inhibition exacerbates stimulation-induced replication stress resulting in stalling of the cell cycle in T cells

Daniel M. Falcon, Chelsea Goff, Sarah Foster Adams

Background PARP inhibitors (PARPi) have significantly improved outcomes for women with ovarian cancer. This is attributed to primary effects on DNA repair pathways that result in synthetic lethality in homologous recombination deficient (HRD) tumor cells. Evidence that PARPi also have immunomodulatory effects …

us (code pays fourni par la source)

A working group report from the 2024 National Cancer Institute / Gynecologic Cancer Steering Committee endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era

Casey M. Cosgrove, Dmitriy Zamarin, Jose Ramon Conejo-Garcia, Kari Hacker et autres

Endometrial cancer is now the leading cause of gynecologic cancer death in the United States. Recognizing the urgent need to improve outcomes for patients diagnosed with endometrial cancer, the National Cancer Institute Gynecologic Cancer Steering Committee convened a clinical trials planning meeting, …

us (code pays fourni par la source)

FIGURE 3 from Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity

Mara P. Steinkamp, Irina V. Lagutina, Kathryn J. Brayer, Fred A. Schultz et autres

Analysis of human cytokine levels in huPDX and non-huPDX models indicates their origin. A–C, Examples of the subtypes of cytokines in huPDX. A, PDX-intrinsic cytokines. B, Immune cell–dependent cytokines. C, Immune cell–influenced cytokines. D–F, Tables of cytokine levels in ascites fluid. Levels …

FIGURE 1 from Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity

Mara P. Steinkamp, Irina V. Lagutina, Kathryn J. Brayer, Fred A. Schultz et autres

Analysis of RNA-seq data comparing ovarian cancer patient samples to non-huPDX samples highlights the importance of immune cells in the patient samples. A, Of the differentially expressed genes that show significantly lower expression in non-huPDX samples (orange) compared with primary ovarian cancer …

FIGURE 7 from Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity

Mara P. Steinkamp, Irina V. Lagutina, Kathryn J. Brayer, Fred A. Schultz et autres

Survival time is reduced in huNBSGW PDX models. A, huNBSGW PDX3, 9, and 18 were engrafted with the same pooled donor CD34+ cells. Survival time was PDX dependent with PDX3 and 9 having a shorter survival time compared with PDX18. Survival curves …

FIGURE 4 from Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity

Mara P. Steinkamp, Irina V. Lagutina, Kathryn J. Brayer, Fred A. Schultz et autres

Detection of TAMs in huNBSGW PDX tumor sections. A, Serial sections of huNBSGW PDX tumor tissue were labeled with human-specific antibodies against a mitochondrial protein to label all human cells and the TAM marker CD68. Scale bar, 100 μm. B, Quantification of …

FIGURE 4 from Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity

Mara P. Steinkamp, Irina V. Lagutina, Kathryn J. Brayer, Fred A. Schultz et autres

Detection of TAMs in huNBSGW PDX tumor sections. A, Serial sections of huNBSGW PDX tumor tissue were labeled with human-specific antibodies against a mitochondrial protein to label all human cells and the TAM marker CD68. Scale bar, 100 μm. B, Quantification of …

FIGURE 2 from Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity

Mara P. Steinkamp, Irina V. Lagutina, Kathryn J. Brayer, Fred A. Schultz et autres

High M-CSF production influences the development of myeloid cells in huNBSGW PDX. A, Diagram of the huPDX study. B, Change in human CD45+ cell populations in peripheral blood before tumor engraftment versus end stage for each mouse (n = 3 mice/group). CD19+ …

FIGURE 2 from Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity

Mara P. Steinkamp, Irina V. Lagutina, Kathryn J. Brayer, Fred A. Schultz et autres

High M-CSF production influences the development of myeloid cells in huNBSGW PDX. A, Diagram of the huPDX study. B, Change in human CD45+ cell populations in peripheral blood before tumor engraftment versus end stage for each mouse (n = 3 mice/group). CD19+ …

FIGURE 1 from Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity

Mara P. Steinkamp, Irina V. Lagutina, Kathryn J. Brayer, Fred A. Schultz et autres

Analysis of RNA-seq data comparing ovarian cancer patient samples to non-huPDX samples highlights the importance of immune cells in the patient samples. A, Of the differentially expressed genes that show significantly lower expression in non-huPDX samples (orange) compared with primary ovarian cancer …